US Patent Issued to BridGene Biosciences on Sept. 9 for "FGFR inhibitors for the treatment of cancer" (California Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,409,177, issued on Sept. 9, was assigned to BridGene Biosciences Inc. (Sunnyvale, Calif.).

"FGFR inhibitors for the treatment of cancer" was invented by Ping Cao (Sunnyvale, Calif.), Chao Zhang (Sunnyvale, Calif.) and Michael J. Bishop (Sunnyvale, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer." ...